Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2016

View Archived Issues

VBI Vaccines develops novel Zika virus vaccine candidate

Synthorx completes Series B financing

Zafgen suspends development of beloranib and refocuses on ZGN-1061

Ionis Pharmaceuticals outlicenses oral antisense drug for GI autoimmune disease

Chronos Therapeutics acquires preclinical CNS programs

FDA approves expansion of Synjardy indication

Ono Pharmaceutical patents EP4 inhibitors

Bristol-Myers Squibb discloses Rho kinase inhibitors

Merck & Co. reports BTK inhibitors

Karos Pharmaceuticals presents tryptophan hydroxylase inhibitors

Teva Pharmaceutical Industries divulges antiviral compounds

Teva Pharmaceutical Industries reports compounds to treat cystic fibrosis

Cerecor awarded grant from NIAAA

FDA grants orphan drug designation to PEG-IL-10 for the treatment of pancreatic cancer

Chugai and Galderma sign license agreement for nemolizumab

EMA grants orphan drug designation to XOMA-358

Immuron and Australian research institutes partner to advance research in autism spectrum disorder

Aegerion to withdraw lomitapide in E.U.

Galenica to acquire Relypsa

Cell Medica's CMD-003 obtains European orphan drug designation

Amylyx Pharmaceuticals to receive funding for phase II study of AMX-0035 in ALS

Heterodimeric interleukin-15 can reduce viral reservoirs in SIV-infected macaques

Maruho and Galderma Pharma update progress made under strategic alliance

PeptiDream licenses peptide discovery platform to Genentech

AbCellera Biologics discloses new antibody collaboration with MassBiologics

Nascent Biotech licenses rights for pritumumab to Hisun in China

Overactive mGlu5 receptor signaling shows promise as a tractable mechanism-based target for OCD

Epclusa efficacy unaffected by negative predictors of virological response